SEC 13F Intelligence

Managers / Q2 2022 · view latest →

Athyrium Capital Management, LP

CIK 0001728001 · 505 FIFTH AVENUE, FLOOR 18, NEW YORK, NY, 10017 · 212-402-6925

Reported Value
$238M
Q2 2022
Positions
11
Filings on Record
21
2019–present window
Filed
Aug 15, 2022
original filing

Summary

Athyrium Capital Management, LP reported $238M in U.S.-listed holdings across 11 positions for Q2 2022.

The portfolio is heavily concentrated: Biora alone accounts for 36.4% of reported value.

Compared with Q1 2022, the fund opened 1 new position and exited 0.

Portfolio Metrics

Turnover
+5.6%
vs prior filed quarter
Largest Position
+36.4%
Biora

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $104MQ4 ’18Q1 ’19: $98MQ2 ’19: $9MQ3 ’19: $5MQ3 ’19Q4 ’20: $208MQ1 ’21: $198MQ2 ’21: $240MQ2 ’21Q3 ’21: $158MQ4 ’21: $280MQ1 ’22: $281MQ1 ’22Q2 ’22: $238MQ3 ’22: $267MQ4 ’22: $238MQ4 ’22Q1 ’23: $279MQ2 ’23: $154MQ3 ’23: $114MQ3 ’23Q4 ’23: $69MQ1 ’24: $73MQ2 ’24: $34MQ2 ’24Q3 ’24: $9Mfilingsflow.com

Portfolio Composition

By security type
US DOMESTIC: 50.8%Other: 46.3%Common Stock: 2.9%
  • US DOMESTIC · 50.8% · $121M
  • Other · 46.3% · $110M
  • Common Stock · 2.9% · $7M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
Paratek Pharmaceuticals Inc.NEW+9.00M9.00M+$8M$8M
Omeros CorpADDED+17.15M35.15M+$7M$20M
CAREMAX INCHELD+04.49M−$17M$16M
Biora Inc.HELD+029.86M−$14M$21M
Amryt Pharma PLCHELD+08.86M−$11M$62M
Biora Inc.HELD+0103.50M−$8M$66M
RVL PHARMACEUTICALS PLCHELD+08.15M−$3M$11M
REPHUSDSocietal CDMO Inc.HELD+02.20M−$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2022

9 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1Biora Inc.Note 7.250% 12/0 · COM36.35%$86M133.36M
2Amryt Pharma PLCSponsored ADS26.04%$62M8.86M
3Omeros CorpNOTE 5.250% 2/1 · NOTE 6.250%11/116.37%$39M56.16M
4CAREMAX INCCOM CL A6.85%$16M4.49M
5RVL PHARMACEUTICALS PLCSHS4.66%$11M8.15M
6BridgeBio Pharma Inc.NOTE 2.250% 2/03.53%$8M20.00M
7Paratek Pharmaceuticals Inc.NOTE 4.750% 5/03.31%$8M9.00M
8PBYIPUMA BIOTECHNOLOGY INChistory →COM2.15%$5M1.79M
9REPHUSDSocietal CDMO Inc.Com0.74%$2M2.20M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2024$9M2Nov 12, 202413F-HRchanges · EDGAR ↗
Q2 2024$34M3Aug 8, 202413F-HRchanges · EDGAR ↗
Q1 2024$73M3May 16, 202413F-HRchanges · EDGAR ↗
Q4 2023$69M3Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$114M6Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$154M7Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$279M8May 16, 2023RESTATEMENTchanges · EDGAR ↗
Q4 2022$238M11Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$267M11Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$238M11Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$281M10May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$280M6Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$158M5Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$240M5Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$198M4May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$208M3Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2019$5M1Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$9M1Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$98M2May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$104M3Feb 12, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.